The Recombinant Human EGF Market is expected to reach a value of over USD 19.1 billion by 2028
During the projection period of 2021 to 2028, the Recombinant Human EGF Market is expected to reach a value of over USD 19.1 billion, growing at a CAGR of over 9.3%.
Because recombinant human EGF is used to treat diabetic ulcers, the global recombinant human EGF market is predicted to develop during the forecast period due to an increase in diabetes cases. According to a report issued in September 2019 by the International Diabetes Federation, the global prevalence of diabetes is predicted to be 9.3 percent, but it is expected to rise to 10.2 percent by 2030. According to the same source, the number of individuals suffering from diabetes worldwide is anticipated to rise by 51% by 2045.
The global recombinant human EGF market is predicted to rise due to increased research and development activities by both public and private entities. A study published in the Medical Military Journal in March 2021, for example, looked into the efficacy of recombinant human EGF in wound healing when combined with vacuum sealing drainage (VSD). Both EGF and VSD are important in wound healing, and when administered together, they are said to enhance improved healing. This is believed to assist shorten treatment times by shortening the time it takes for wounds to heal. These advancements are expected to open up new markets for recombinant human EGF.
Coronavirus (COVID – 19) Pandemic Impact on the Global Recombinant Human EGF Market
On December 31, 2019, a COVID-19 epidemic was first detected in Wuhan, China. According to the World Health Organization's Coronavirus (COVID-19) Weekly Epidemiological Update, about 180 million cases and 3.9 million fatalities due to Coronavirus (COVID-19) were documented worldwide up until June 27, 2021.
The COVID-19 pandemic has impacted numerous markets around the world, including the worldwide recombinant human EGF market, where demand and supply are projected to be hampered. The COVID-19 epidemic has caused a slew of surgical procedures to be halted, including a number of non-emergency treatments. According to a 2019 article released by the National Centre for Biotechnology Information, the COVID-19 pandemic caused approximately 1.1 million cases of ophthalmological surgeries in Monte Carlo to come to a halt, with surgical procedures not being completed after registration during the pandemic. The market for recombinant human EGF is predicted to be hampered as a result of this.
Comments
Post a Comment